Posted in | News | Medical Robotics

Health Robotics Launches i.v.STATION ONCO

Health Robotics has revealed its great success at the 2011 Annual Symposium of the European Association of Hospital Pharmacists (EAHP) in Vienna, with respect to its robots CytoCare and i.v.STATION.

Gaspar DeViedma, the Executive Vice President of Health Robotics was given an invitation to share the financial, clinical and throughput/efficiency outcomes obtained from the global installation of its robots at 45 locations. DeViedma’s first task was to thank the hospital participants in the program named i.v.STATION Beta-Test. This program  concluded by January 2011. Later, he spoke about the results obtained from the installations after the finish of the Beta-Tests. He specified that the outcomes included an average ROI of six months, an average throughput of 35 patient specific IV dosages per hour, with no drug exchange errors and no labeling errors, with no details of cross-contamination and drug quantity, which are ISO7886-1 compliant and the 100% success achieved in sterility.

According to De Viedma, the hosting visits in the i.v.STATION hospitals have a gone a long way to prove the benefits, flexibility and the features included in the production environment. The i.v.SOFT Assist and the i.v.STATION, which are being used productively, could be verified by  industry experts and  prospective customers, especially with regard to its much admired vision to develop beyond Oncology Automation. He further mentioned that an added benefit was gained from the successful outcomes, which was  the capacity to re-use the majority of the completely tested i.v.STATION tools along with the company’s new robot i.v.STATION ONCO, much before their competitors were able to justify their claims of handling chemotherapy automation for the past twenty years or more.

After the keynote address, DeViedma introduced the new robot for cancer therapy the i.v.STATION ONCO. He also disclosed the throughput/efficiency and clinical outcomes, which were experienced by hospitals at the Asia-Pacific, European and American hospitals while using the CytoCare, which was the first ever robot for cancer therapy. To conclude, DeViedma commented that the company was highly appreciative of the i.v.STATION Betas in America, where there were several delays in installations mainly because of the ex-distributors of Health Robotics’ refusal to take part in the Beta-Test installations, which led to the hiring of the local engineering staff. The company was eagerly waiting to repeat the Beta Tests with the new i.v.STATION ONCO and the TPNstation robots during 2011 and 2012 respectively. This time the control of the tests would not be handed over to the distribution partners of Health Robotics, which would eliminate delays and help in completing the tests on time.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Health Robotics. (2019, February 21). Health Robotics Launches i.v.STATION ONCO. AZoRobotics. Retrieved on June 14, 2024 from

  • MLA

    Health Robotics. "Health Robotics Launches i.v.STATION ONCO". AZoRobotics. 14 June 2024. <>.

  • Chicago

    Health Robotics. "Health Robotics Launches i.v.STATION ONCO". AZoRobotics. (accessed June 14, 2024).

  • Harvard

    Health Robotics. 2019. Health Robotics Launches i.v.STATION ONCO. AZoRobotics, viewed 14 June 2024,

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.